Ticker LaunchReverse merger · Pending · SLTE
Slate Medicines, Inc.
Reverse merger with Fulcrum Therapeutics, Inc. (FULC)
Slate Medicines, Inc. agreed to merge into Fulcrum Therapeutics, Inc. (FULC), a Nasdaq-listed biotech that evaluated strategic alternatives before the merger, in a reverse merger that takes the private company public. The deal was announced on Aug 17, 2026. The combined company is expected to trade as Slate Medicines, Inc. (SLTE) on Nasdaq.
Slate Medicines is a biotechnology company developing migraine therapeutics. Its lead candidate, SLTE-1009, is a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody for migraine prevention, and it also has a bispecific antibody in lead optimization.
- Status
- Pending
- Private company
- Slate Medicines, Inc.
- Public company
- Fulcrum Therapeutics, Inc. (FULC)
- Public company business before
- Nasdaq-listed biotech that evaluated strategic alternatives before the merger
- Announced
- Aug 17, 2026
- Combined company
- Slate Medicines, Inc. (SLTE)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- 8-K merger agreement announcement Aug 17, 2026
- Press release Aug 17, 2026
- S-4/A (registration/proxy) Oct 8, 2026
- All filings on EDGAR CIK 1680581
Other pending reverse mergers
- North Immunology, Inc.into Aethlon Medical, Inc. · Sep 17, 2026
- Santersus AGinto Xenetic Biosciences, Inc. · Sep 16, 2026
- Ambros Therapeutics, Inc.into Werewolf Therapeutics, Inc. · Aug 21, 2026
- Redx Pharma Limitedinto Skye Bioscience, Inc. · Aug 14, 2026
- Caldera Therapeutics, Inc.into Synlogic, Inc. · Jul 29, 2026
- GH Power Inc.into Matinas BioPharma Holdings, Inc. · Jul 13, 2026